Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review

Dasatinib is a potent and effective second‐generation oral tyrosine kinase inhibitor that is clinically indicated for the treatment of imatinib‐resistant or imatinib‐intolerant breakpoint cluster region‐Abelson (BCR‐ABL)‐positive chronic myeloid leukaemia (CML) or for Philadelphia chromosome‐positiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chao‐Chin, Hsu, Jui‐Feng, Wu, Kuan‐Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103079/
https://www.ncbi.nlm.nih.gov/pubmed/33976882
http://dx.doi.org/10.1002/rcr2.753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103079/
https://www.ncbi.nlm.nih.gov/pubmed/33976882
http://dx.doi.org/10.1002/rcr2.753

Ejemplares similares